A phase I, double-blind, randomised, placebo-controlled, dose escalating study to assess the safety, tolerability, and pharmacokinetics of single and multiple doses of NVB302 administered orally to healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 29 Apr 2016
At a glance
- Drugs NVB 302 (Primary)
- Indications Bacterial infections; Clostridium-difficile-infections
- Focus Adverse reactions
- 23 Oct 2012 Actual end date changed from 21 Dec 2011 to 16 Mar 2012 as reported by ISRCTN.
- 23 Oct 2012 Actual initiation date changed from 24 Aug 2011 to 26 Oct 2011 as reported by ISRCTN.
- 22 Dec 2011 Actual end date (Dec 2011) added as reported by ISRCTN: Current Controlled Trials.